Representative publications

Real-world clinical evidence in human therapeutics

Stocking JC, et al. A Least Absolute Shrinkage and Selection Operator-derived predictive model for postoperative respiratory failure in a heterogeneous adult elective surgery patient population. CHEST Critical Care 2023;1:1000025.

Obeng-Kusi M, et al. No margin for non-adherence: probabilistic Kaplan-Meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study). Leukemia Research 2021;111:106734.

Alrawashdh N, et al. Survival trends in chronic lymphocytic leukemia across treatment eras: SEER database analyses (1985–2017). Annals of Hematology 2021;100:2501-2512.

Almutairi AR, et al. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis from the SEER-Medicare database. Expert Opinion on Drug Safety 2021;20:489-497.

MacDonald KM, et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Review of Clinical Immunology 2019;15:553-569.

London G, et al. Long-term treatment with biosimilar epoetin-α (HX575) in haemodialysis patients with renal anaemia: real-world effectiveness and safety in the MONITOR-CKD5 study. Clinical Nephrology 2018;89:1-9. 

Bokemeyer C, et al. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. Supportive Care in Cancer 2017;25:1819-1828.

Yun S, et al. Potential benefit of low-dose candesartan in trastuzumab-induced cardiotoxicity. JAMA Oncology 2017;3:279-280.

Aapro M, et al. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: patterns, outcomes, and determinants (MONITOR-GCSF study). Journal of Geriatric Oncology 2017;8:86-95.

Aapro M, et al. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Annals of Oncology 2016;27:2039-2045.

MacDonald K, et al. Modeling of blood pressure outcomes in patients with and without cardiovascular or renal disease treated with valsartan (the PREVIEW study). Archives of Cardiovascular Diseases 2013;106:124-134.

Abraham I, et al. Modeling of treatment response to erythropoiesis-stimulating agents in older (age > 70 years) and younger (age < 70 years) cancer patients with anemia: findings from the Anemia Cancer Treatment study. Journal of Geriatric Oncology 2013;4:196-201.

Delforge M, et al. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. Annals of Hematology 2011;90:655-666.

Brusselle G, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respiratory Medicine 2009;103:1633-1642.

Aapro M, et al. Modeling of outcomes and response rates to treatment with erythropoiesis stimulating agents in cancer patients with anemia: findings from the Anemia Cancer Treatment (A.C.T.) study. Annals of Oncology 2009;20:1714-1721. 

Noens L, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-5411.

Steeman E, et al. Implementation of discharge management for geriatric patients at risk for readmission and institutionalization. International Journal for Quality in Health Care 2006;18:352-358.

Rossert J, et al. Effect of early correction of anemia on the progression of CKD. American Journal of Kidney Diseases 2006;47:738-750. 

Birgegård G, et al. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. European Journal of Haematology 2006;77:378-386.

Barrett-Lee P, et . Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 2005;10:743-757.

Seshadri T, et al. The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancer. Medical Journal of Australia 2005;182:453-457.

Rosencher N, et al. Blood management in elective knee and hip arthroplasty in Europe. Transfusion 2003;43:59-69.

Ludwig H, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer 2004;40:2293-2306.

Vanrenterghem Y, et al. Prevalence and management of anemia in renal transplant patients: a European Survey. American Journal of Transplantation 2003;3:835-845.

Vincent JL, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002;288:1499-1507.

Valderrabano F, et al. European Survey on Anemia Management (ESAM). Nephrology Dialysis Transplantation 2000;15:Supplement 4 (Special Issue on the pan-European ESAM study; 8 articles).

De Geest S, et al. Late acute rejections and subclinical noncompliance with cyclosporine therapy in heart transplant patients. Journal of Heart and Lung Transplantation 1998;17:854-863.

De Geest S, et al. Incidence, determinants, and consequences of subclinical non-compliance with immunosuppressive therapy in renal patients. Transplantation 1995;59:340-347.

Disclosure: The publications listed here blend articles reporting on studies and projects contracted to MATRIX45 and predecessor companies, independent projects initiated by MATRIX45, as well as academic projects by Ivo Abraham’s academic research groups.